P-glycoprotein mediates the efflux of quinidine across the blood-brain barrier

Journal of Pharmacology and Experimental Therapeutics

Volumn 283, Issue 2, 1997, Pages 574-580

  Kusuhara, Hiroyuki ^a   Suzuki, Hiroshi ^a   Terasaki, Tetsuya ^b   Kakee, Atsuyuki ^a   Lemaire, Michel ^c   Sugiyama, Yuichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ETHER; GLYCOPROTEIN P; MACROGOL 200; MANNITOL; QUINIDINE; VALSPODAR; VERAPAMIL;

ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CORTEX; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG DIFFUSION; DRUG ELIMINATION; DRUG TRANSPORT; INTRACEREBRAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MICROINJECTION; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PARTITION COEFFICIENT; PASSIVE TRANSPORT; PRIORITY JOURNAL; RAT;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CYCLOSPORINS; MALE; MICE; MICE, KNOCKOUT; P-GLYCOPROTEIN; QUINIDINE; RATS; RATS, WISTAR;

EID: 0030817412     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. BOESCH, D. AND LOOR, F.: Extent and persistence of P-glycoprotein inhibition in multidrug-resistant P388 cells after exposure to resistance-modifying agents. Anti-Cancer Drugs 5: 229-238, 1994.
2. BOOTE, D. J., DENNIS, I. F., TWENTYMAN, P. R., OSBORNE, R. J., LABURTE, C., HENSEL, S., SMYTH, J. F., BRAMPTON, M. H. AND BLEEHEN, N. M.: Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J. Clin. Oncol. 14: 610-618, 1996.
3. HARASHIMA, H., SAWADA, Y., SUGIYAMA, Y., ICA T. AND HANANO, M.: Analysis of nonlinear tissue distribution of quinidine in rats by physiologically based pharmacokinetics. J. Pharmacokinet. Biopharmacol. 13: 425-440, 1985.
4. HIGGINS, C. F. AND GOTTESMAN, M. M.: Is the multidrug transporter a flippase? Trends Biochem. Sci. 17: 18-21, 1992.
5. HOMOLYA, L., HOLLO, Z., GERMANN, U. A., PASTAN, I., GOTTESMAN, M. M. AND SARKADI, B.: Fluorescent cellular indicators are extruded by the multidrug resistance protein. J. Biol. Chem. 268: 21493-21496, 1993.
6. HOLLO, Z., HOMOLYA, L., DAVIS, C. W. AND SAKKADI, B.: Calcein accumulation as a fluorometric functional assay of the multidrug transporter. Biochim. Biophys. Acta 1191: 384-388, 1994.
7. IZQUIERDO, M. A., SCHEFFER, G. L., FLENS, M. J., GIACCONE, G., BROXTERMAN, H. J., MEIJER, C. J., VAN DER VALK, P. AND SCHEPER, R. J.: Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors. Am. J. Pathol. 148: 877-887, 1996.
8. JETTE, L., POULIOT, J. F., MURPHY, G. F. AND BELIVEAU, R.: Isoform I (mdr3) is the major form of P-glycoprotein expressed in mouse brain capillaries. Biochem. J. 305: 761-766, 1995.
9. KAKEE, A., TERASAKI, T. AND SUGIYAMA, Y.: Brain efflux index as a novel method of analyzing efflux transport at the blood-brain barrier. J. Pharmacol. Exp. Ther. 277: 1550-1559, 1996.
10. KELLER, R. P., ALTERMATT, H. J., DONATSCH, P., ZIHLMANN, H., LAISSUE J. A. AND HIESTAND, P. C.: Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity. Int. J. Cancer 51: 433-438, 1992.
11. KIM, S. Y. AND BENOWITZ, N. L.: Poisoning due to class IA antiarrhythmic drugs quinidine, procainamide and disopyramide. Drug Safety 5: 393-420, 1990.
12. LEMAIRE, M., BRUELISAUER, A., GUNTZ, P. AND SATO, H.: Dose-dependent brain penetration of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin, in rats. Cancer Chemother. Pharmacol. 38: 481-486, 1996.
13. LEVIN, V. A: Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J. Med. Chem. 23: 682-684, 1980.
14. OHNISHI, T., TAMAI, I., SAKANAKA, K., SAKATA, A., YAMASHIMA, T., YAMASHITA, J. AND TSUJI, A.: In vivo and in vitro evidence for ATP-dependency of P-glycoprotein-mediated efflux of doxorubicin at the blood-brain barrier. Biochem. Pharmacol. 49: 1541-1544, 1995.
15. PATLAK, C. S., BLASBERG, R. G. AND FENSTERMACHER, J. D.: Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J. Cereb. Blood Flow Metab. 3: 1-7, 1983.
16. RUSHING, D. A., RABER, S. R., RODVOLD, K. A., PISCITELLI, S. C., PLANK, G. S. AND TEWKSBURY, D. A.: The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer. Cancer 74: 834-841, 1994.
17. SAKATA, A., TAMAI, I., KAWAZU, K., DEGUCHI, Y., OHNISHI, T., SAHEKI, A. AND TSUJI, A.: In vivo evidence for ATP-dependent and P-glycoprotein-mediated transport of cyclosporin A at the blood-brain barrier. Biochem. Pharmacol. 48: 1989-1992, 1994.
18. SCHEFFER, G. L., WIJNGAARD, P. L. J., FLENS, M. L., IZQUIERDO, M. A., SLOVAK, M. L., PENEDO, H. M., MEIJER, C. J. L. M., CLEVERS, H. C. AND SCHEPER, R. J.: The drug resistance-related protein LRP is the human major vault protein. Nat. Med. 1: 578-582, 1995.
19. SCHINKEL, A. H., SMIT, J. J. M., VAN TELLINGEN, O., BEIJNEN, J. H., WAGENAAR, E., VAN DEEMTER, L., MOL, C. A. A. M., VAN DER VALK, M. A., ROBANUS-MANDAAG, E. C., TE RIELE, H. P. J., BERNS, A. J. M. AND BORST, P.: Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77: 491-502, 1994.
20. SCHINKEL, A. H., WAGENAAR, E., VAN DEEMTER, L., MOL, C. A. A. M. AND BORST, P.: Absence of the mdrla P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Invest. 96: 1698-1705, 1995.
21. SCHUURHUIS, G. J., BROXTERMAN, H. J., DE LANGE, J. H. M., PINEDO, H. M., VAN HEIJNINGEN, T. H. M., KUIPER, C. M., SCHEFFER, G. L., SCHEPER, R. J., VAN KALKEN, C. K., BAAK, J. P. A. AND LANKELMA, J.: Early multidrug resistance, defined by changes in intracellular doxorubicin distribution, independent of P-glycoprotein. Br. J. Cancer 64: 857-861, 1991.
22. SUGIYAMA, Y. AND SUZUKI, H.: Kinetic analysis of drug transport through the blood-brain barrier and blood-CSF barrier. Proc. Int. Symp. Control. Release of Bioact. Mater. 24: 217-218, 1997.
23. SUZUKI, H., TERASAKI, T. AND SUGIYAMA, Y.: Role of efflux transport across the, blood-brain barrier and blood-cerebrospinal fluid barrier on the disposition of xenobiotics in the central nervous system. Adv. Drug Deliv. Rev. 25: 257-285, 1997.
24. TATSUTA, T., NAITO, M., OH-HARA, T., SUGAWARA, I. AND TSURUO, T.: Functional involvement of P-glycoprotein in blood-brain barrier. J. Biol. Chem. 267: 20383-20391, 1992.
25. TRIGUERO, D., BUCIAK, J. AND PARDRIDGE W. M.: Capillary depletion method for quantification of blood-brain barrier transport of circulating peptides and plasma proteins. J. Neurochem. 54: 1882-1888, 1990.
26. TSUJI, A., TERASAKI, T., TAKABATAKE, Y., TENDA, Y., TAMAI, I., YAMASHIMA, T., MORITANI, S., TSURUO, T. AND YAMASHITA, J.: P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells. Life Sci. 51: 1427-1437, 1992.
27. TSUJI, A., TAMAI, I., SAKATA, A., TENDA, Y. AND TERASAKI, T.: Restricted transport of cyclosporin A across the blood-brain barrier by a multidrug transporter, P-glycoprotein. Biochem. Pharmacol. 46: 1096-1099, 1993.
28. WANG, Q., YANG, H. AND ELMQUIST, W. F.: The effect of LY-335979 on the distribution kinetics of quinidine to the brain: An in vivo microdialysis study in freely-moving rats [Abstract]. Pharm. Res. 13: S-456, 1996.
29. YAMAOKA, K., TANIGAWARA, T., NAKAGAWA, T. AND UNO, T.: A pharmacokinetic analysis program (MULTI) for microcomputer. J. Pharmacobio-dyn. 4: 879-885, 1981.
30. +-independent multispecific anion transporter mediates active transport of pravastatin into rat liver. Am. J. Physiol. 264: G36-G44, 1993.